When was CPTx founded?

CPTx was founded in 2021 and raised its 1st funding round 3 years after it was founded.

Where is CPTx located?

CPTx is headquartered in Planegg, Germany.

Who is the current CEO of CPTx?

Hendrik Dietz of CPTx. They have also founded 1 company.

How many employees does CPTx have?

As of Jul 31, 2026, the latest employee count at CPTx is 49.

Is CPTx a funded company?

CPTx is a funded company, having raised a total of $***** in its 1st and only funding round, a Series B round on Sep 27, 2024.

When was the latest funding round of CPTx?

CPTx's latest funding was a $***** Series B round on Sep 27, 2024, with participation from 6 investors.

Where does CPTx rank among its competitors?

CPTx ranks 1186th amongst 3543 active competitors, of which 1177 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of CPTx?

CPTx's top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

CPTx - 2026 Company Profile, Team, Funding & Competitors

CPTx is a series B company based in Planegg (Germany), founded in 2021 by Hendrik Dietz. It operates as a Developer of programmable DNA therapeutics for a range of medical challenges. CPTx has raised $29M in funding from BlueYard and SPRIND. The company has 3543 active competitors, including 1177 funded and 838 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.

Company Details

Developer of programmable DNA therapeutics for a range of medical challenges. The company leverages its proprietary technology to deliver precision medicine solutions, utilizing a programmable DNA-based approach to target specific diseases such as viruses, cancer, and autoimmune diseases.

Website: cptx.bio
Email ID: *****@cptx.bio
Phone Number: +49 **********

Key Metrics

Founded Year

2021

Location

Planegg, Germany

Stage

Series B

Total Funding

$29M in 1 round

Latest Funding Round

Series B, Sep 27, 2024, $*****

Investors

BlueYard & 5 more

Ranked

1186^th among 3543 active competitors

Employee Count

49 as on Jul 31, 2026

Similar Companies

Jazz Pharmaceuticals & 3296 more

View CPTx's full profile

CPTx has raised a total funding of $29M over 1 round. Its latest funding round was a Series B round on Sep 27, 2024 for $*****. 6 investors participated in its latest round. CPTx has 4 institutional investors and 2 angel investors.

Here is the list of recent funding rounds of CPTx:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 27, 2024	4258585	Series B	7141201	8808298	9541639	9406922

Access funding benchmarks and valuations. Sign up today!

View details of CPTx's funding rounds and investors

The founders of CPTx is Hendrik Dietz. Hendrik Dietz is the CEO of CPTx.

Here are the details of CPTx's key team members:

Hendrik Dietz: Co-Founder & CEO of CPTx.

View details of CPTx's Founder profiles and Board Members

CPTx's employee count trend

CPTx has 49 employees as of Jul 26. Here is CPTx's employee count trend over the years:

Uncover CPTx's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of CPTx include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of CPTx, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	80/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, Google Ventures & 18 others	74/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
6th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	71/100
9th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
1186th	CPTx 2021, Planegg (Germany), Series B	Developer of programmable DNA therapeutics for a range of medical challenges	$29M	Bayern Kapital, BlueYard & 4 others	39/100